iiinova — where your digital self keeps evolving

Pierre Gholam MD @livermd.bsky.social · 16/10/2025

@bsky.app I don’t know that I feel comfortable handing out very personal information to verify I’m an adult. Please find a better way or I’m moving on.

010

Pierre Gholam MD @livermd.bsky.social · 15/10/2025

Effective rx for severe Alcohol Associated Steatohepatitis #ASH is the greatest unmet need in #hepatology It fills hospital beds & kills people in their prime Yet… A cursory look shows >40 clinical stage ph2/3 #MASH studies vs (maybe) 3 for ASH We need to get our priorities straight… #liversky

011

Pierre Gholam MD @livermd.bsky.social · 20/09/2025

Thrilled to be at the @davaoncology.bsky.social summit on GI malignancies. I had the pleasure of speaking on the topics of the intersection of incretins and cancer as well as the declining incidence of #HCC #liversky

130

Pierre Gholam MD @livermd.bsky.social · 11/09/2025

The voluntary withdrawal of Ocaliva by Intercept for PBC is not a cause for celebration. It is certainly not an action that enhances the safety of the American public by protecting it from a nefarious, hepatotoxic drug. Ocaliva is not troglitazone or bromfenac. #liversky

210

Pierre Gholam MD @livermd.bsky.social · 20/08/2025

More great news this time for European patients living with #MASH with F2/F3 fibrosis with the approval of #Rezdiffra™ (#resmetirom) by the @ema.europa.eu Rezdiffra is included in the @easlnews.bsky.social guidelines as FL therapy and is the first approved MASH medication in the EU. #liversky

010

Pierre Gholam MD @livermd.bsky.social · 18/08/2025

More #efruxifermin data this time in #MASH F2/F3 fibrosis @ 96 weeks ✅ Efficacy w/ dose dependent response (sort of) and NITs consistent ↔️ not crazy about mITT though it is mentioned no paired bx= non responders ⬇️ dose dependent reduction in bone mineral density #liversky

051

Pierre Gholam MD @livermd.bsky.social · 16/08/2025

The @fda.gov just approved @novonordisk.bsky.social #wegovy on an accelerated path for #MASH F2/F3 fibrosis We now have 2 approved drugs with different MOA and that’s great news for patients. I anticipate at least 5 more approvals in the next 5 years. #liversky

131

Pierre Gholam MD @livermd.bsky.social · 01/08/2025

Since #orforglipron is in the news, a helpful timeline: There isn't a PDUFA (Prescription Drug User Fee Act) date set yet but @elilillyandcompany.bsky.social has indicated they plan to submit for @US_FDA approval in Q3/4 2025 If approved, it could be available in Q4 2025 or 2026 #liversky

120

Pierre Gholam MD @livermd.bsky.social · 22/07/2025

We are looking forward to rolling out dual cut off reporting for liver stiffness measurement (LSM) and spleen stiffness measurement (SSM) which will aid in more accurately ruling in and out clinically significant portal hypertension (CSPH) and enhance clinical trial capability. #liversky

010

Pierre Gholam MD @livermd.bsky.social · 17/07/2025

Jaume Bosch No one, and I mean no one, made more seminal contributions to the measurement, interpretation & clinical applications of HVPG, the prognostic impact of CSPH and its rx. Truly in the pantheon of all time greatest hepatologists and a kind, generous person on top. RIP #liversky

062

Pierre Gholam MD @livermd.bsky.social · 28/05/2025

Last 24 hours in #beirut. Anise cookies, Arabic coffee and traditional cups

040

Pierre Gholam MD @livermd.bsky.social · 15/05/2025

This evening, @ohioliver.bsky.social awarded its inaugural Liver Champion award to Dr. Anthony Post “for decades of excellence, advocacy and commitment to northeast Ohioans with liver disease” Thanks to all who joined us and made this a memorable event! #liversky

051

Pierre Gholam MD @livermd.bsky.social · 12/05/2025

Join @ohioliver.bsky.social on May 14 at 630 pm at the Embassy suites hotel in Independence OH for Tavill Liver rounds. We will be honoring Dr. Anthony Post with our inaugural liver champion award! #liversky

010

Reposted by Pierre Gholam MD

The Baveno Cooperation: an EASL Consortium @bavenocoop.bsky.social · 09/05/2025

🇬🇧 CALIBRE trial – D. Tripathi at #EASL2025 RCT: carvedilol vs VBL for 1º prevention in cirrhosis 🟰 No difference in bleeding or survival at 12 months 💊 Carvedilol safe, simpler & cost-effective 📉 Follow-up limited (12 mo), but extension planned ⚠️ Underpowered due to COVID

131

Pierre Gholam MD @livermd.bsky.social · 09/05/2025

Highlights of @docberza.bsky.social talk on NITs @easlnews.bsky.social #easlcongress We need to use @bavenocoop.bsky.social dual stiffness cutoffs more often and u suspect this is the way of the future. #liversky

053

Pierre Gholam MD @livermd.bsky.social · 07/05/2025

Exhibitor booths are not usually meeting highlights but this is an exception. Kudos to @boehringerglobal.bsky.social on this artistic rendition on the theme of liver health and disease @easlnews.bsky.social #EASLCongress #livertwitter

030

Pierre Gholam MD @livermd.bsky.social · 06/05/2025

I would venture to say that for @umich.edu this was a swing and a miss. Always be weary of people who chase after an even more outrageous compensation than the one they are getting and are willing to change jobs like they change underwear…

nytimes.com

University President Who Shut Down D.E.I. Efforts Is Recruited to Florida

000

Pierre Gholam MD @livermd.bsky.social · 05/05/2025

Amsterdam bound to attend @easlnews.bsky.social #easlcongress Looking forward to learning, connecting with old friends and making new ones! #liversky

020

Pierre Gholam MD @livermd.bsky.social · 02/05/2025

Out of all current FDA approvals: DM, overweight/obese, death RR in CV disease, delay in renal disease progression in CV/DM and OSA… PAYERS ONLY RELIABLY COVER DM Are PBMs suddenly going to loosen up their purses because there is a #MASH indication? I’ll believe it when I see it… #liversky

000

Pierre Gholam MD @livermd.bsky.social · 28/04/2025

A delightful assortment of Lebanese mezze at Sky Lounge Parma today!

010

Pierre Gholam MD @livermd.bsky.social · 15/04/2025

Early returns on my #resmetirom #rezdiffra #MASH patients at 1 year. So far 7/8 patients reasessed with LSM have a 30% or greater reduction. Hopefully we start getting some real world data to complement the open label trial. #liversky

040

Pierre Gholam MD @livermd.bsky.social · 12/04/2025

Because all the cool kids are doing it! I look like an older version of me plus some cosmetic surgery. #liversky

020

Pierre Gholam MD @livermd.bsky.social · 10/04/2025

Time for the liver community to say it loudly, nonjudgementally & consistently: There is no safe level of alcohol consumption @easlnews.bsky.social is leading the way to defend mandatory labels on alc. beverages in the EU. It’s time for @aasldnews.bsky.social to do the same in the US #liversky

031

Pierre Gholam MD @livermd.bsky.social · 09/04/2025

Every once in a while you see a #HBV patient on long term nucs who seroconverts for over a year and you take them off nucs and all is well with the world. #liversky

030

Pierre Gholam MD @livermd.bsky.social · 06/04/2025

The @uhcougars.bsky.social mount a furious comeback against @dukemensbasketball.bsky.social & snatch victory from the jaws of defeat. I will be donating to the Greater Cleveland Food bank on behalf of @uhhospitals.bsky.social transplant institute! #ncaatournament #MarchMadness #DukeHouston

010

Pierre Gholam MD @livermd.bsky.social · 04/04/2025

The first ever @fda.gov approved treatment for IgG4-RD is upon us. #inebilizumab #uplizna @amgen.bsky.social A much needed option for this very heterogenous and challenging disease which can literally affect any organ but prominently liver and bile ducts. #liversky #gisky

041

Pierre Gholam MD @livermd.bsky.social · 04/04/2025

The label for #inebilizumab #uplizna is very broad. Before starting: ✅ serum immunoglobulins & consult immunology if low ✅HBV status. Consult GI/Hep if HBsAg or HBcAb pos ✅TB status and consult ID if positive ✅ do not administer live or attenuated vaccines #liversky #gisky

010

Pierre Gholam MD @livermd.bsky.social · 04/04/2025

Summary of the @nejm.org paper which summarizes the RCT MITIGATE trial which led to the @fda.gov approval of #inebilizumab #gisky #liversky

020

Pierre Gholam MD @livermd.bsky.social · 29/03/2025

Peter Marks did more yesterday to oppose the status quo of ignorance and anti-science than everything the democrats have done since January. He should run for office as an independent. More people like him should do the same.

010

Pierre Gholam MD @livermd.bsky.social · 26/03/2025

A good day for patients with neuroendocrine tumors with @fda.gov approval of #cabozantinib for advanced pancreatic and extra pancreatic disease #liversky

010

Pierre Gholam MD @livermd.bsky.social · 25/03/2025

Listen. I’m not proud of this. ChatGPT helped out. But it’s funny and topical…

000

Pierre Gholam MD @livermd.bsky.social · 24/03/2025

On a rare personal note, today marks my father’s 90th birthday. From surviving metastatic colon cancer to being buried under his home in 2020 during the explosion that destroyed #Beirut, he has survived and thrived. Every day is a blessing.

010

Pierre Gholam MD @livermd.bsky.social · 20/03/2025

@lilydaramd.bsky.social gives a fantastic overview of all things immune mediated hepatitis with a focus on immune mediated liver injury from checkpoint inhibitors (ILICI) #liverconnect25 #liversky

010

Pierre Gholam MD @livermd.bsky.social · 20/03/2025

Dr. Zobair Younossi kicks off #liverconnect2025 with a summary of the impressive roster of activities completed in 2024 and great things to come this year. #liversky

000

Pierre Gholam MD @livermd.bsky.social · 20/03/2025

It’s a great day to be in San Antonio for CLDF #Liverconnect25. So many fantastic educational offerings and one of my favorite meetings! #LIVERSKY

010

Pierre Gholam MD @livermd.bsky.social · 12/03/2025

The VA is vital to fulfilling a sacred pledge to those who gave it all, to care for them at a time of need. Caring for veterans is not wasteful. If you’ve worked a day at the VA, you’ll know that it is already under-resourced. We need to spend more to make the VA better not gut it.

usnews.com

000

Reposted by Pierre Gholam MD

Northeast Ohio Liver Alliance @ohioliver.bsky.social · 11/03/2025

Congratulations NORD for leading National Rare Disease Day on February 28th. So much was accomplished this year with the involvement of various patient groups. As a Cleveland-based group, it was wonderful to see the Terminal Tower lit up in celebration. rarediseases.activehosted.com/index.php?ac...

011

Pierre Gholam MD @livermd.bsky.social · 07/03/2025

Has anyone seen a woman with severe itching, a low/normal alkphos over 10 years, a biopsy that shows minimal fibrosis, mild interface hepatitis and bile duct injury and a sky high AMA titer, SP-100 and GP-210? Symptomatic PBC with normal alkphos? Treat or not? #Liversky

212

Pierre Gholam MD @livermd.bsky.social · 06/03/2025

Full house for the 59th edition of Tavill Citywide Liver rounds! #liversky

020

Pierre Gholam MD @livermd.bsky.social · 27/02/2025

It’s 2025 and 20 people in Texas are hospitalized with disseminated measles. A child has died..of measles

000

Pierre Gholam MD @livermd.bsky.social · 27/02/2025

Anyone who has worked at the VA will forever have appreciation for our vets. They deserve our support and the very best of care for PTS and other illnesses We must stand for our vets and against cuts to VA facilities across the nation. Contact your rep & senator now. #medsky #gisky #liversky

1134

Pierre Gholam MD @livermd.bsky.social · 23/02/2025

NEOLA is in the house! (Or the sky!) Come to our first liver rounds on March 5! #liversky #gisky

010